BACH PHARMA, INC. - LEADERS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
Bach Pharma, Inc. Is Dedicated to the Development of New Therapeutics for the Treatment of Life-Threatening Neurodegenerative Diseases.
What is GVT?
GVT®, is a novel cytoprotective agent with promising powerful anti-oxidant and anti-inflammatory properties.
GVT has the potential to treat serious diseases of the central nervous and immune systems, as many are associated with oxidative stress and inflammatory pathways.
Who is Bach Pharma?
Bach Pharma, Inc., a privately held company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life-threatening diseases.
Bach’s lead program is targeting degenerative neurological illnesses with the goal to dramatically improve patients' lives and reduce the cost of global health care.
How Can You Help?
The goal of BACH Pharma is to allow those suffering from neuroimmuno-degenerative illnesses access to a product that can help them regain their quality of life. To do this, we need to complete four more phases in our research and FDA approvals. If you, or someone you know suffers from GWI, ALS, Parkinson's, Alzheimer's, or other similar conditions, and you want them to have access to GVT, then we need your help.
Click here to see how you can help BACH Pharma on our way to create a world that's free of these terrible diseases.
About Bach Pharma
Bach Pharma, Inc., (BACH), a privately held pharmaceutical company is a global leader in the development of revolutionary phthalazinedione-based therapeutics...
Bach is dedicated to developing drugs that modulate fundamental pathways regulating redox status and oxidative injury, thus normalizing the cellular redox...
Bach Pharma is targeting serious and life threatening diseases in which oxidative stress plays a role. This includes neuroimmuno-degenerative illnesses...